Although the link between VDR activation and P-gp expression in endothelial cells is well established, it is unclear whether potential dysregulation of the VDR-P-gp pathway under PD pathological conditions (e.g., oxidative stress and α-synuclein aggregation) can be reversed by VDR ligand treatment. The gene discussed is PGP; the disease is Parkinson disease.